Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VistaGen Therapeutics and Vala Sciences have entered into a strategic collaboration to advance drug safety screening methodologies in the clinically relevant human in vitro bioassay systems.
Subscribe to our email newsletter
Vala will use its Kinetic Image Cytometer platform to demonstrate the suitability and utility of VistaGen’s human pluripotent stem cell derived-cardiomyocytes for screening new drug candidates.
VistaGen’s human cardiomyocyte-based bioassay system, CardioSafe 3D, will permit Vala to demonstrate the resolution and applicability.
Sensitive and reproducible measurement of electrophysiological responses of stem cell-derived cardiomyocytes to new drug candidates is a key element of VistaGen’s CardioSafe 3D drug rescue programs.
VistaGen chief executive officer Shawn Singh said the collaboration with Vala directly supports the core drug rescue applications of our Human Clinical Trials in a Test Tube platform.